- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01005121
Colchicine for Diabetic Nephropathy
January 3, 2013 updated by: Prof.Avi Livneh
Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function tests will be monitored.
The investigators' hypothesis is that colchicine will diminish proteinuria and might also help slow down the development of end stage renal failure in the long run.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shaye Kivity, MD
- Phone Number: 03-5302436
- Email: kivitys@gmail.com
Study Locations
-
-
-
Ramat gan, Israel, 52621
- Recruiting
- Sheba Medical Center, Tel Hashomer
-
Contact:
- Shaye Kivity, MD
- Phone Number: 03-5302436
- Email: kivitys@gmail.com
-
Sub-Investigator:
- Shaye Kivity, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with DM aging 18+, able to sign an informed consent.
- 24 hour protein collection between 0.5-6 mg during the last 6 months prior enrollment.
- Hemoglobin A1c in the range of 6-9%, stable for the last year (0.5±)
- Creatinine lower than 1.5 mg/dL.
- Blood pressure lower than 150/90 mmHg on stable anti-hypertensive treatment for at least 3 months.
- Treated with ACE & ARB, unless contraindicated
Exclusion criteria:
- Malignancy or significant heart, lung or liver disease.
- Any GI disease, IBD, malnutrition ( BMI under 18 )
- Psychiatric disease
- Any muscle disease, history of rhabdomyelysis, myopathy or myositis.
- Any disease causing renal injury/proteinuria apart from DM
- Any inflammatory or autoimmune disease
- Any infection during the last month.
- Use of potentially nephrotoxic drugs.
- Woman in child bearing age that do not use at least one contraceptive device.
- Pregnant or lactating woman.
- Participation in another study during the last 3 months.
- Alcohol or drug abusers
- Anyone whom the investigators conclude are not appropriate
- Any patient receiving steroids.
- Any patient with Colchicine allergy, or treated with the drug during the last two weeks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: colchicine
patients will receive 2 mg of colchicine daily
|
2mg, per-os, once daily for six months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
24 hr urine protein collection
Time Frame: every 2 months
|
every 2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Anticipated)
December 1, 2014
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
October 29, 2009
First Submitted That Met QC Criteria
October 29, 2009
First Posted (Estimate)
October 30, 2009
Study Record Updates
Last Update Posted (Estimate)
January 4, 2013
Last Update Submitted That Met QC Criteria
January 3, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-09-7369-AL-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathy
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina
-
University of Sao Paulo General HospitalCompleted
-
Chinese PLA General HospitalCompletedInsulin Pump Therapy in Treating Diabetic Nephropathy
-
Assiut UniversityNot yet recruitingType 2 DM é Diabetic Nephropathy
-
PfizerTerminatedType 2 Diabetic NephropathyUnited States
-
Chang Gung Memorial HospitalUnknown
Clinical Trials on colchicine
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR)CompletedAtrial Fibrillation | Thoracic SurgeryCanada
-
Population Health Research InstituteRecruitingInflammation | Peripheral Arterial Disease | Atherosclerosis of ExtremitiesCanada
-
Wuhan Union Hospital, ChinaCompletedCoronary Artery Disease | Percutaneous Coronary InterventionChina
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedObesity | Metabolic DiseaseUnited States
-
Montreal Heart InstituteCompletedMyocardial Infarction | Coronary Artery DiseaseCanada
-
University of the RyukyusCompletedCoronary Artery Disease | Inflammation | Diabetes Mellitus, Type 2 | Diarrhea | Colchicine | White Blood CellJapan
-
Assistance Publique - Hôpitaux de ParisCompletedColchicine Resistance | Mediterranean FeverFrance
-
Elpen Pharmaceutical Co. Inc.Withdrawn
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingPercutaneous Coronary Intervention | Elderly Patients | Multivessel Coronary Artery Disease | C-Reactive ProteinChina